Vistagen Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2015
Filed with the SEC on Nov 16, 2015 and accepted by EDGAR at Nov 13, 2015, 19:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2015-07-01 to 2015-09-30 | −$5.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2015-04-01 to 2015-09-30 | −$7.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-07-01 to 2015-09-30 | $12.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2015-04-01 to 2015-09-30 | $767.3k | us-gaap:InterestExpense |
| Income tax | 6 months2015-04-01 to 2015-09-30 | $2.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-07-01 to 2015-09-30 | −$7.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2015-04-01 to 2015-09-30 | −$36.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-07-01 to 2015-09-30 | −$5.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2015-04-01 to 2015-09-30 | −$24.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-07-01 to 2015-09-30 | −$5.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2015-04-01 to 2015-09-30 | −$24.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-07-01 to 2015-09-30 | 1,624,371 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2015-04-01 to 2015-09-30 | 1,592,104 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2015-04-01 to 2015-09-30 | −$2.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2015-09-30 | $694.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-09-30 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-09-30 | $1.9m | us-gaap:Assets |
| Current liabilities | At period end2015-09-30 | $2.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-09-30 | $3.3m | us-gaap:Liabilities |
| Long-term debt | At period end2015-09-30 | $31.4k | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2015-09-30 | −$1.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001415889-15-003716. Last ingested by Listed: Oct 30, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.